Drug Profile
House dust mite allergy ultra-short course therapy - Allergy Therapeutics
Alternative Names: Acarovac MPL; Acarovac QuattroLatest Information Update: 15 Jun 2023
Price :
$50
*
At a glance
- Originator Allergy Therapeutics
- Class Allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Allergic rhinitis
Most Recent Events
- 15 Jun 2023 House dust mite allergy ultra-short course therapy is still in phase I trials for Allergic-rhinitis in Spain (Allergy Therapeutics pipeline, June 2023)
- 15 Jun 2023 Phase-II clinical trials in Allergic rhinitis (Parenteral) (Allergy Therapeutics pipeline, June 2023)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Allergic-rhinitis in Spain (Parenteral)